Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

GeoVax Labs Receives $0.8M Funding Boost from NIAID to Progress HIV Vaccine

Firm’s $3.6 million grant for 2011-2012 increased to $4.4 million, taking total five-year award up to $20.4 million. GeoVax Labs has had an existing $3.6 million annual grant from the National Institute of Allergy and Infectious Diseases (NIAID) increased to $

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Firm’s $3.6 million grant for 2011-2012 increased to $4.4 million, taking total five-year award up to $20.4 million.

GeoVax Labs has had an existing $3.6 million annual grant from the National Institute of Allergy and Infectious Diseases (NIAID) increased to $4.4 million, to further support development of the firm’s HIV vaccine. The firm announced receipt of the designated $3.6 million tranche just a couple of weeks ago.

The five-year Integrated Preclinical/Clinical AIDS Vaccine Development grant was originally awarded in 2007, and the latest $0.8 million increase reflects an administrative supplement to support vaccine response characterization, GeoVax states.

This supplement for the 2011–12 grant year is the third for the GeoVax program, bringing the initial award of $15.4 million now to an aggregate of $20.4 million. “This award is important for the advancement of our GM-CSF adjuvanted vaccine that is achieving an unprecedented level of prevention of infection,” comments Harriet Robinson, Ph.D., GeoVax CSO. The firm had originally projected developing the vaccine for use in controlling existing HIV infection, but says it has observed that administration of the vaccine also provides high levels of preventive protection.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What Are Dosages of HIV Vaccine?

Pending FDA approval for therapeutic vaccination to elicit immune responses against a wide variety of HIV antigens Administered every 3 months and used in conjunction with ART or HAART antiviral drugs

Source: www.rxlist.com ↗
02Why the HIV Vaccine Has Been Hard to Develop

Researchers have studied HIV vaccines for almost a quarter-century, but they have not yet found one that works. There are several reasons for this. In general, vaccines act in similar ways to a natural infection, which means your body makes antibodies to kill the virus. But HIV doesn't seem to activate this kind of response. There are no cases of a person who is HIV-positive who developed an immune response that successfully fought the infection. Researchers are still trying to figure out how to set off the right kind of immune response for HIV. Another stumbling block for scientists is that most vaccines use a weak or inactivated version of the germ to start your body's immune response. But that doesn't seem to work well for HIV, and a vaccine with a live virus is too risky to use.

Source: www.webmd.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

02
Peptide Therapy Guide Editorial Team

HIV Vaccine: Could One Prevent or Treat It?

HIV drugs have vastly improved the quality of life for people living with HIV and AIDS, but they can't yet cure the infection. Someone at high risk for HIV can take a pill to help prevent an infection, but the…

Read guide →